{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/",
 "dataUrl": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/data.json",
 "title": "Crinetics Pharmaceuticals (CRNX) Stock Forecast (2026)",
 "description": "Crinetics Pharmaceuticals, Inc. (CRNX) stock: Healthcare, Biotechnology. $9.0B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Crinetics Pharmaceuticals, Inc. (CRNX)",
 "published": "2026-07-14T09:19:46+00:00",
 "modified": "2026-09-15T15:21:24.938+00:00",
 "generated": "2026-09-16T11:00:27.062Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "CRNX",
  "name": "Crinetics Pharmaceuticals, Inc.",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Biotechnology",
  "country": "United States",
  "website": "https://www.crinetics.com"
 },
 "quote": {
  "price": 84.95,
  "previousClose": 84.95,
  "change": 0,
  "changePercent": 0,
  "open": 84.95,
  "high": 84.95,
  "low": 84.95,
  "volume": 0,
  "averageVolume": 2404548,
  "marketCap": 9012787664,
  "fiftyTwoWeekHigh": 85.010002,
  "fiftyTwoWeekLow": 28.73,
  "marketOpen": false,
  "asOf": "2026-09-15T15:21:24.000Z"
 },
 "statistics": {
  "pe": -17.16161554509943,
  "eps": -5.05,
  "dividendYield": 0,
  "beta": 0.088,
  "priceToSales": 213.79607,
  "priceToBook": 7.5410557,
  "revenueTtm": 42156000,
  "grossMargin": 0.9938689386097619,
  "returnOnEquity": -0.42446
 },
 "technicals": {
  "rsi": 86.96,
  "macd": 2.06,
  "sma50": 76.81,
  "sma200": 50.87,
  "rsiSignal": "Overbought",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Hold",
  "score": 53,
  "consensus": "Hold",
  "fairValue": 84.95,
  "analystTarget": 87.07,
  "analystCount": 9,
  "wallStreetConsensus": "Hold",
  "generatedAt": "2026-09-15T15:21:24.000Z",
  "priceAtAnalysis": 84.95,
  "volatility": {
   "daily": 0.12,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Neutral",
  "conservativeEntry": 84.1,
  "aggressiveEntry": 84.95,
  "stopLoss": 81.07,
  "stopLossPercent": 3.6,
  "targets": [
   86.62,
   88.31,
   90.83
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 49.92,
    "base": 94.74,
    "upside90th": 179.82
   },
   {
    "year": 2028,
    "downside10th": 42.69,
    "base": 105.67,
    "upside90th": 261.52
   },
   {
    "year": 2029,
    "downside10th": 38.84,
    "base": 117.85,
    "upside90th": 357.56
   },
   {
    "year": 2030,
    "downside10th": 36.49,
    "base": 131.43,
    "upside90th": 473.48
   },
   {
    "year": 2031,
    "downside10th": 34.98,
    "base": 146.59,
    "upside90th": 614.3
   },
   {
    "year": 2032,
    "downside10th": 34.02,
    "base": 163.49,
    "upside90th": 785.53
   },
   {
    "year": 2033,
    "downside10th": 33.46,
    "base": 182.33,
    "upside90th": 993.5
   },
   {
    "year": 2034,
    "downside10th": 33.2,
    "base": 203.35,
    "upside90th": 1245.63
   },
   {
    "year": 2035,
    "downside10th": 33.17,
    "base": 226.8,
    "upside90th": 1550.68
   },
   {
    "year": 2036,
    "downside10th": 33.34,
    "base": 252.94,
    "upside90th": 1918.98
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "CRNX Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$84.95",
    "Day Range": "$84.95 to $84.95",
    "Prev Close": "$84.95",
    "52-Week Range": "$28.73 to $85.01",
    "Market Cap": "$9.01B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis On price-to-sales, the yardstick used here in place of P/E, CRNX trades at 213.80x, far above the sector average of 3.70x."
   ]
  },
  {
   "id": "financials",
   "title": "CRNX Financial Performance",
   "text": [
    "Analysis: In the last 4 quarters, CRNX beat estimates 3 times. The stock rose 2 times the next day. Price tends to react positively to beats."
   ]
  },
  {
   "id": "analysis",
   "title": "CRNX Analysis",
   "text": [
    "At $84.95, Crinetics Pharmaceuticals is trading above its 50-day Simple Moving Average (SMA) of $76.81 and its 200-day SMA of $50.87, indicating a bullish short-to-medium term trend. The Relative Strength Index (RSI) is at 86.96, firmly in overbought territory, suggesting the stock may be due for a pullback. The Moving Average Convergence Divergence (MACD) is positive at 2.06, supporting the current upward momentum. Key support levels are now established around the 50-day SMA at $76.81, while resistance is being tested near the current price. The RSI's overbought condition, coupled with the 'Moderate Sell Signal' from insider transactions, warrants caution despite the bullish trend indicated by moving averages. Investors should monitor for any signs of reversal as the stock approaches potential resistance levels.",
    "Crinetics Pharmaceuticals has reported exceptional revenue growth of 2336.3%, indicating strong market traction and potential for future profitability.",
    "Insiders have net sold $13.1 million in stock with no reported purchases, signaling a potential lack of short-term confidence in the current valuation.",
    "The Relative Strength Index (RSI) is at 86.96, indicating the stock is in overbought territory and may be due for a price correction.",
    "Several analysts have recently downgraded CRNX from 'Buy' to 'Hold' or 'Neutral', reflecting a shift in sentiment towards caution.",
    "Crinetics Pharmaceuticals (CRNX) is expected to maintain its current valuation range in the near term, with analysts setting a median price target of $85, which aligns with its current trading price. The company's extraordinary revenue growth of over 2300% suggests significant market adoption or pipeline success, which could drive future earnings. However, the path to profitability remains a key question, with current EPS estimates for the next year at -4.01. The company's strong balance sheet and low debt provide a cushion for continued investment in growth. The outlook hinges on the company's ability to translate its rapid revenue expansion into sustainable profitability. Positive developments in its drug pipeline, successful clinical trial results, or strategic partnerships could act as catalysts for upside. Conversely, continued net losses, failure to meet future earnings expectations, or a broader market rotation away from growth stocks could pressure the stock lower, potentially testing support levels around the 50-day SMA of $76.81."
   ],
   "lists": {
    "ProTips": [
     "Monitor the RSI closely for any signs of a pullback from its current overbought level of 86.96.",
     "Given the 'Moderate Sell Signal' from insider transactions, investors should exercise caution and consider the implications of $13.1 million in net sales.",
     "As a biotechnology company, keep abreast of clinical trial results and regulatory approvals, which are critical catalysts for future growth and valuation."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Strong Revenue Growth Trajectory",
     "text": "Crinetics Pharmaceuticals has reported exceptional revenue growth of 2336.3%, indicating strong market traction and potential for future profitability.",
     "source": "Company Filings"
    },
    {
     "type": "Bearish",
     "title": "Insider Selling Activity",
     "text": "Insiders have net sold $13.1 million in stock with no reported purchases, signaling a potential lack of short-term confidence in the current valuation.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "Overbought Technical Conditions",
     "text": "The Relative Strength Index (RSI) is at 86.96, indicating the stock is in overbought territory and may be due for a price correction.",
     "source": "Technical Analysis"
    },
    {
     "type": "Neutral",
     "title": "Analyst Downgrades",
     "text": "Several analysts have recently downgraded CRNX from 'Buy' to 'Hold' or 'Neutral', reflecting a shift in sentiment towards caution.",
     "source": "Analyst Ratings"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Crinetics Pharmaceuticals (CRNX) exhibits a high price-to-sales ratio of 213.80, significantly above the sector median of 3.7, reflecting its growth-stage biotechnology profile. The company's profit margin is reported at a remarkable 86.02%, though this is juxtaposed with a significantly negative operating margin of -527.35% and a negative EPS of -5.05, indicating substantial operational costs or research and development expenses are outweighing revenue at this stage. The return on equity is a negative -42.45%, consistent with a loss-making enterprise. Compared to the Healthcare sector's median revenue growth of 8.1%, CRNX's 2336.3% growth is exceptional. However, this growth comes at the cost of profitability, as evidenced by the negative EPS and operating margin. The company's debt-to-equity ratio stands at a very low 0.04, suggesting a strong balance sheet with minimal leverage. The current valuation appears stretched based on traditional profitability metrics, but may be justified by its rapid revenue expansion and future growth potential as assessed by analysts.",
    "Crinetics Pharmaceuticals' most recent reported earnings for the quarter ending June 2026 showed an EPS of -1.14, beating the estimated -1.18 by 3.39% and resulting in a slight positive price change of 0.12%. Prior to this, the company reported an EPS of 0.05 for the quarter ending March 2026, significantly beating estimates of -0.12% with a 141.67% surprise and a 0.65% stock price increase. However, the company has a history of negative EPS, with a reported loss of -1.23 for the quarter ending March 2026 missing estimates by 2.5% and leading to a -13.82% price drop. The overall trend indicates volatile earnings performance with occasional beats on estimates, but persistent net losses.",
    "The primary risk for Crinetics Pharmaceuticals is its current lack of profitability, with a negative EPS of -5.05 and a significantly negative operating margin of -527.35%, which could deter investors seeking immediate returns. Also, the stock is trading in overbought territory according to its RSI of 86.96, suggesting a potential for a near-term price correction. Insider selling, with $13.1 million in net sales versus no purchases, also presents a cautionary signal regarding management's short-term confidence in the stock's valuation."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "9.01B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "N/A (Negative EPS)"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "-5.05"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "85.01"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "28.73"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Overbought SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($76.81) above the 200-day SMA ($50.87), price action is firmly bullish above key moving averages, RSI at 87.0 indicates overbought conditions; consider caution for immediate entries."
   ],
   "facts": {
    "RSI": "Overbought",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "86.96"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "2.06"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "76.81"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "50.87"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.28",
    "Correlation with Nasdaq 100 (QQQ)": "+0.22",
    "Correlation with Bitcoin (BTC)": "+0.21",
    "Correlation with Gold (XAU)": "+0.01"
   }
  },
  {
   "id": "trade-plans",
   "title": "CRNX Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Enter now if confident",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (87.0) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$86.62",
    "TARGET 2": "$88.31",
    "TARGET 3": "$90.83",
    "STOP LOSS": "$81.07"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "-7.46%",
    "Average Feb return": "-1.83%",
    "Average Mar return": "-6.60%",
    "Average Apr return": "+7.36%",
    "Average May return": "-3.46%",
    "Average Jun return": "-0.26%",
    "Average Jul return": "+9.93%",
    "Average Aug return": "+5.85%",
    "Average Sep return": "+8.59%",
    "Average Oct return": "+2.74%",
    "Average Nov return": "+7.59%",
    "Average Dec return": "+5.09%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "0.12%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in CRNX in July 2018 would be worth about $34,659 today, compared with about $27,224 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in CRNX today could grow to about $29,775 by 2036 in the base case, with a bull case near $225,895 and a bear case around $3,925. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "CRNX Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $131 for CRNX by 2030 in the base case, from $84.95 today (1.5x over 4 years). The downside path ends near $36.49. These are outcomes of a Monte Carlo simulation run on CRNX's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using CRNX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. CRNX is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "CRNX simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$49.92",
        "$94.74",
        "$180"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$42.69",
        "$106",
        "$262"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$38.84",
        "$118",
        "$358"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$36.49",
        "$131",
        "$473"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$34.98",
        "$147",
        "$614"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$34.02",
        "$163",
        "$786"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$33.46",
        "$182",
        "$993"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$33.20",
        "$203",
        "$1,246"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$33.17",
        "$227",
        "$1,551"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$33.34",
        "$253",
        "$1,919"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "CRSP CRISPR Therapeutics AG NASDAQ $51.83 -2.13%",
     "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
    },
    {
     "text": "ELV Elevance Health, Inc. NYSE $419.17 -1.20%",
     "url": "https://clearank.com/stock/elv-stock-analysis/"
    },
    {
     "text": "CAPR Capricor Therapeutics, Inc. NASDAQ $8.81 +5.26%",
     "url": "https://clearank.com/stock/capr-stock-analysis/"
    },
    {
     "text": "IQV IQVIA Holdings Inc. NYSE $269.67 +1.51%",
     "url": "https://clearank.com/stock/iqvia-iqv/"
    },
    {
     "text": "ZTS Zoetis Inc. NYSE $73.43 -0.33%",
     "url": "https://clearank.com/stock/zts-stock-analysis/"
    },
    {
     "text": "HCA HCA Healthcare, Inc. NYSE $425.76 +0.06%",
     "url": "https://clearank.com/stock/hca-healthcare-hca/"
    },
    {
     "text": "BIIB Biogen Inc. NASDAQ $216.17 -0.55%",
     "url": "https://clearank.com/stock/biib-stock-analysis/"
    },
    {
     "text": "LEGN Legend Biotech Corporation NASDAQ $17.67 -4.64%",
     "url": "https://clearank.com/stock/legend-biotech-legn/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "VOO vs VT Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/voo-vs-vt/"
    },
    {
     "text": "UBER vs LYFT Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/uber-vs-lyft/"
    },
    {
     "text": "MSFT vs TSLA Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/msft-vs-tsla/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "CRNX Insider Trading Analysis",
   "facts": {
    "Bought": "None",
    "Sold": "$13.1M",
    "Insiders": "13",
    "Avg Transaction": "$571.4K"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in CRNX",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Mar 20, 2019",
       "cells": [
        "VIVO CAPITAL VIII, L.L.C. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "417.0K",
        "$9.3M"
       ]
      },
      {
       "label": "Nov 3, 2023",
       "cells": [
        "STRUTHERS RICHARD SCOTT Chief Executive Officer",
        "Sell",
        "200.0K",
        "$6.1M"
       ]
      },
      {
       "label": "Jan 22, 2019",
       "cells": [
        "5AM VENTURES IV, L.P. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "262.2K",
        "$5.7M"
       ]
      },
      {
       "label": "Jun 21, 2019",
       "cells": [
        "5AM VENTURES IV, L.P. Unknown",
        "Sell",
        "250.0K",
        "$5.6M"
       ]
      },
      {
       "label": "May 8, 2024",
       "cells": [
        "STRUTHERS RICHARD SCOTT Chief Executive Officer",
        "Sell",
        "107.4K",
        "$5.3M"
       ]
      },
      {
       "label": "Apr 17, 2020",
       "cells": [
        "VIVO CAPITAL VIII, L.L.C. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "330.6K",
        "$5.1M"
       ]
      },
      {
       "label": "Apr 7, 2020",
       "cells": [
        "VIVO CAPITAL VIII, L.L.C. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "306.1K",
        "$4.2M"
       ]
      },
      {
       "label": "Mar 18, 2019",
       "cells": [
        "5AM VENTURES IV, L.P. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "154.8K",
        "$3.8M"
       ]
      },
      {
       "label": "Apr 13, 2022",
       "cells": [
        "STRUTHERS RICHARD SCOTT Chief Executive Officer",
        "Sell",
        "138.6K",
        "$3.7M"
       ]
      },
      {
       "label": "Apr 8, 2026",
       "cells": [
        "KNIGHT JEFF E Chief Operating Officer",
        "Sell",
        "85.2K",
        "$3.4M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Crinetics+Pharmaceuticals%2C+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is CRNX's current stock price and consensus rating?",
   "answer": "Crinetics Pharmaceuticals (CRNX) is currently trading at $84.95. The consensus rating among Wall Street analysts is 'Hold', with a median price target of $85."
  },
  {
   "question": "Is Crinetics Pharmaceuticals stock a buy right now?",
   "answer": "With a 'Hold' consensus rating and the stock trading at its median price target, CRNX is not presenting a clear buy signal. The RSI is overbought at 86.96, and insider selling indicates caution, suggesting investors may want to wait for a more favorable entry point or clearer positive catalysts."
  },
  {
   "question": "What are the key technical indicators for CRNX stock?",
   "answer": "CRNX is trading above its 50-day and 200-day moving averages ($76.81 and $50.87), indicating a bullish trend. However, its RSI is at 86.96, signaling overbought conditions, which could precede a pullback."
  },
  {
   "question": "How has Crinetics Pharmaceuticals performed in recent earnings reports?",
   "answer": "Recent earnings reports show mixed results, with some quarters beating EPS estimates, such as the quarter ending March 2026 (0.48 actual vs 0.44 estimate). However, the company consistently reports net losses, with an EPS of -1.14 for the quarter ending June 2026."
  },
  {
   "question": "What is the revenue growth for Crinetics Pharmaceuticals?",
   "answer": "Crinetics Pharmaceuticals has demonstrated exceptional revenue growth, reporting an increase of 2336.3% year-over-year. This rapid expansion is a key driver for the company's valuation despite its current unprofitability."
  },
  {
   "question": "What are the main risks facing Crinetics Pharmaceuticals?",
   "answer": "Key risks include the company's current unprofitability, with negative EPS and operating margins, and the stock trading in overbought technical territory. Significant insider selling also adds a layer of caution."
  },
  {
   "question": "What is CRNX's stock forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, Crinetics Pharmaceuticals' stock forecast for 2030 shows a base case price of $131.43, with a downside projection of $36.49 and an upside projection of $473.48. These are statistical outcomes, not guarantees."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "CRSP",
    "name": "CRISPR Therapeutics AG NASDAQ",
    "price": "$51.83",
    "change": "-2.13%",
    "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
   },
   {
    "ticker": "ELV",
    "name": "Elevance Health, Inc. NYSE",
    "price": "$419.17",
    "change": "-1.20%",
    "url": "https://clearank.com/stock/elv-stock-analysis/"
   },
   {
    "ticker": "CAPR",
    "name": "Capricor Therapeutics, Inc. NASDAQ",
    "price": "$8.81",
    "change": "+5.26%",
    "url": "https://clearank.com/stock/capr-stock-analysis/"
   },
   {
    "ticker": "IQV",
    "name": "IQVIA Holdings Inc. NYSE",
    "price": "$269.67",
    "change": "+1.51%",
    "url": "https://clearank.com/stock/iqvia-iqv/"
   },
   {
    "ticker": "ZTS",
    "name": "Zoetis Inc. NYSE",
    "price": "$73.43",
    "change": "-0.33%",
    "url": "https://clearank.com/stock/zts-stock-analysis/"
   },
   {
    "ticker": "HCA",
    "name": "HCA Healthcare, Inc. NYSE",
    "price": "$425.76",
    "change": "+0.06%",
    "url": "https://clearank.com/stock/hca-healthcare-hca/"
   },
   {
    "ticker": "BIIB",
    "name": "Biogen Inc. NASDAQ",
    "price": "$216.17",
    "change": "-0.55%",
    "url": "https://clearank.com/stock/biib-stock-analysis/"
   },
   {
    "ticker": "LEGN",
    "name": "Legend Biotech Corporation NASDAQ",
    "price": "$17.67",
    "change": "-4.64%",
    "url": "https://clearank.com/stock/legend-biotech-legn/"
   }
  ],
  "comparisons": [
   {
    "ticker": "VOO vs VT Comparison",
    "name": "",
    "url": "https://clearank.com/compare/voo-vs-vt/"
   },
   {
    "ticker": "UBER vs LYFT Comparison",
    "name": "",
    "url": "https://clearank.com/compare/uber-vs-lyft/"
   },
   {
    "ticker": "MSFT vs TSLA Comparison",
    "name": "",
    "url": "https://clearank.com/compare/msft-vs-tsla/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "EXC",
    "text": "Exelon Corp.",
    "url": "https://clearank.com/stock/exc-stock-analysis/"
   },
   {
    "ticker": "GWW",
    "text": "W.W. Grainger Inc.",
    "url": "https://clearank.com/stock/gww-stock-analysis/"
   },
   {
    "ticker": "CDE",
    "text": "Coeur Mining Inc.",
    "url": "https://clearank.com/stock/cde-stock-analysis/"
   },
   {
    "ticker": "CCI",
    "text": "Crown Castle Inc.",
    "url": "https://clearank.com/stock/cci-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "ARB/USD",
    "text": "↑ 19.42%",
    "url": "https://clearank.com/crypto/arbitrum-arb-usd/"
   },
   {
    "ticker": "INJ/USD",
    "text": "↓ 11.80%",
    "url": "https://clearank.com/crypto/injective-inj/"
   },
   {
    "ticker": "CRV/USD",
    "text": "↓ 11.53%",
    "url": "https://clearank.com/crypto/crv-usd-crypto-analysis/"
   },
   {
    "ticker": "CRCL",
    "text": "↓ 11.41%",
    "url": "https://clearank.com/stock/circle-internet-group-crcl/"
   },
   {
    "ticker": "TEM",
    "text": "↑ 10.67%",
    "url": "https://clearank.com/stock/tempus-ai-tem/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "BNTX",
    "text": "BioNTech SE",
    "url": "https://clearank.com/stock/bntx-stock-analysis/"
   },
   {
    "ticker": "CAPR",
    "text": "Capricor Therapeutics, Inc.",
    "url": "https://clearank.com/stock/capr-stock-analysis/"
   },
   {
    "ticker": "CRSP",
    "text": "CRISPR Therapeutics AG",
    "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
   },
   {
    "ticker": "FBRX",
    "text": "Forte",
    "url": "https://clearank.com/stock/fbrx-stock-analysis/"
   },
   {
    "ticker": "IONS",
    "text": "Ionis",
    "url": "https://clearank.com/stock/ions-stock-analysis/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/CRNX-crinetics-pharmaceuticals-crnx-analysis-2026-07.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/CRNX-crinetics-pharmaceuticals-crnx-analysis-2026-07.png",
     "width": "1280",
     "height": "720",
     "caption": "Crinetics Pharmaceuticals (CRNX) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/",
        "name": "Crinetics Pharmaceuticals (CRNX) STOCK Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/#webpage",
     "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/",
     "name": "Crinetics Pharmaceuticals (CRNX) Stock Forecast (2026)",
     "datePublished": "2026-07-14T09:19:46+00:00",
     "dateModified": "2026-09-15T15:21:24+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/CRNX-crinetics-pharmaceuticals-crnx-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/#richSnippet",
     "headline": "Crinetics Pharmaceuticals (CRNX) Stock Forecast (2026)",
     "name": "Crinetics Pharmaceuticals (CRNX) Stock Forecast (2026)",
     "description": "Crinetics Pharmaceuticals, Inc. (CRNX) stock: Healthcare, Biotechnology. $9.0B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-07-14T09:19:46+00:00",
     "dateModified": "2026-09-15T15:21:24+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "Crinetics Pharmaceuticals, Inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "CRNX"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NASDAQ"
       }
      ],
      "description": "Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing oral therapies for rare endocrine diseases and endocrine-related tumors. The company’s current portfolio centers on medicines designed to address conditions driven by hormone dysregul",
      "tickerSymbol": "CRNX",
      "sameAs": "https://www.crinetics.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/CRNX-crinetics-pharmaceuticals-crnx-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is CRNX's current stock price and consensus rating?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Crinetics Pharmaceuticals (CRNX) is currently trading at $84.95. The consensus rating among Wall Street analysts is 'Hold', with a median price target of $85."
     }
    },
    {
     "@type": "Question",
     "name": "Is Crinetics Pharmaceuticals stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "With a 'Hold' consensus rating and the stock trading at its median price target, CRNX is not presenting a clear buy signal. The RSI is overbought at 86.96, and insider selling indicates caution, suggesting investors may want to wait for a more favorable entry point or clearer positive catalysts."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key technical indicators for CRNX stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "CRNX is trading above its 50-day and 200-day SMAs, indicating a bullish trend. However, its RSI is at 86.96, signaling overbought conditions, which could precede a pullback."
     }
    },
    {
     "@type": "Question",
     "name": "How has Crinetics Pharmaceuticals performed in recent earnings reports?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Recent earnings reports show mixed results, with some quarters beating EPS estimates, such as the quarter ending March 2026 (0.48 actual vs 0.44 estimate). However, the company consistently reports net losses, with an EPS of -1.14 for the quarter ending June 2026."
     }
    },
    {
     "@type": "Question",
     "name": "What is the revenue growth for Crinetics Pharmaceuticals?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Crinetics Pharmaceuticals has demonstrated exceptional revenue growth, reporting an increase of 2336.3% year-over-year. This rapid expansion is a key driver for the company's valuation despite its current unprofitability."
     }
    },
    {
     "@type": "Question",
     "name": "What are the main risks facing Crinetics Pharmaceuticals?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Key risks include the company's current unprofitability, with negative EPS and operating margins, and the stock trading in overbought technical territory. Significant insider selling also adds a layer of caution."
     }
    },
    {
     "@type": "Question",
     "name": "What is CRNX's stock forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Crinetics Pharmaceuticals' stock forecast for 2030 shows a base case price of $131.43, with a downside projection of $36.49 and an upside projection of $473.48. These are statistical outcomes, not guarantees."
     }
    }
   ]
  }
 ]
}